These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 33910874)

  • 1. Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer.
    Kubota Y; Yoshimura K; Hamada K; Hirasawa Y; Shida M; Taniguchi M; Matsui H; Ariizumi H; Ishiguro T; Suzuki N; Ohkuma R; Sambe T; Ishida H; Horiike A; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Kobayashi S; Tsunoda T
    In Vivo; 2021; 35(3):1865-1875. PubMed ID: 33910874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report.
    Yamaguchi K; Tsuchihashi K; Tsuji K; Kito Y; Tanoue K; Ohmura H; Ito M; Isobe T; Ariyama H; Kusaba H; Akashi K; Baba E
    Medicine (Baltimore); 2021 May; 100(19):e25773. PubMed ID: 34106609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.
    Aoki M; Shoji H; Nagashima K; Imazeki H; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Higuchi K; Boku N
    ESMO Open; 2019; 4(3):e000488. PubMed ID: 31231567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1
    Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
    Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
    Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
    Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
    Kim SH; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study.
    Petrioli R; Mazzei MA; Giorgi S; Cesqui E; Gentili F; Francini G; Volterrani L; Francini E
    Anticancer Drugs; 2020 Feb; 31(2):190-195. PubMed ID: 31850916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
    Aoki M; Kadowaki S; Takahashi N; Suzuki T; Oshima K; Ando T; Yamamoto Y; Kawakami K; Kito Y; Matsumoto T; Shimozaki K; Miyazaki Y; Yamaguchi T; Nagase M; Tamura T; Amanuma Y; Esaki T; Miura Y; Akiyoshi K; Baba E; Makiyama A; Negoro Y; Nakashima K; Sugimoto N; Nagashima K; Shoji H; Boku N
    Gastric Cancer; 2023 Jan; 26(1):132-144. PubMed ID: 36316527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.
    Ota Y; Takahari D; Suzuki T; Osumi H; Nakayama I; Oki A; Wakatsuki T; Ichimura T; Ogura M; Shinozaki E; Suenaga M; Chin K; Yamaguchi K
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):265-272. PubMed ID: 31907646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases.
    Nakamura N; Kinami S; Fujita J; Kaida D; Tomita Y; Miyata T; Fujita H; Takamura H; Ueda N; Kosaka T
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):2955-2960. PubMed ID: 33112554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
    Namikawa T; Yokota K; Tanioka N; Fukudome I; Iwabu J; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Surg Today; 2020 Nov; 50(11):1486-1495. PubMed ID: 32542414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer.
    Arigami T; Matsushita D; Okubo K; Yanagita S; Ehi K; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Uenosono Y; Ishigami S; Natsugoe S
    Oncology; 2020; 98(9):630-636. PubMed ID: 32428899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer.
    Takada S; Murooka H; Tahatsu K; Yanase M; Umehara K; Hashishita H; Toru H; Satoru M; Sagawa T; Fujikawa K; Sato H; Mino K
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):695-701. PubMed ID: 35225483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Kim CG; Hong M; Jeung HC; Lee G; Chung HC; Rha SY; Kim HS; Lee CK; Lee JH; Han Y; Kim JH; Lee SY; Kim H; Shin SJ; Baek SE; Jung M
    Eur J Cancer; 2022 Sep; 172():387-399. PubMed ID: 35839733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy.
    Yamada T; Hayashi T; Inokuchi Y; Hayashi K; Watanabe H; Komori K; Kano K; Shimoda Y; Fujikawa H; Shiozawa M; Morinaga S; Rino Y; Masuda M; Ogata T; Oshima T
    Target Oncol; 2020 Jun; 15(3):317-325. PubMed ID: 32319020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).
    Tanaka K; Tanabe H; Sato H; Ishikawa C; Goto M; Yanagida N; Akabane H; Yokohama S; Hasegawa K; Kitano Y; Sugiyama Y; Uehara K; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Sato K; Yuzawa S; Tanino M; Taruiishi M; Sumi Y; Mizukami Y; Fujiya M; Okumura T
    Cancer Med; 2022 Jan; 11(2):406-416. PubMed ID: 34845844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neutrophil-Lymphocyte Ratio as a Prognostic Indicator in Patients Treated with Nivolumab for Gastric Cancer].
    Fujita K; Haruki N; Kurehara H; Ochi N; Yamakawa Y; Harata S; Tsumoto C; Tsuji T; Ito T; Izumi A; Usui R; Shinoda N
    Gan To Kagaku Ryoho; 2020 Jun; 47(6):923-926. PubMed ID: 32541169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.
    Nakatani Y; Kawakami H; Ichikawa M; Yamamoto S; Otsuka Y; Mashiko A; Takashima Y; Ito A; Nakagawa K; Arima S
    Invest New Drugs; 2018 Aug; 36(4):726-731. PubMed ID: 29623482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.